These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 15652229)

  • 1. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
    Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
    J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
    Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
    Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
    Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds.
    Svihálková-Sindlerová L; Foltinová V; Vaculová A; Horváth V; Soucek K; Sova P; Hofmanová J; Kozubík A
    Anticancer Res; 2010 Apr; 30(4):1183-8. PubMed ID: 20530425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
    Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
    Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
    Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
    Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
    Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
    Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.